Literature DB >> 19302929

Doripenem: antimicrobial profile and clinical potential.

David M Livermore1.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19302929     DOI： 10.1016/j.diagmicrobio.2009.02.012

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


× No keyword cloud information.
  8 in total

1.  Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study.

Authors:  James A Karlowsky; Andrew J Walkty; Heather J Adam; Melanie R Baxter; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

2.  Pharmacodynamic variability beyond that explained by MICs.

Authors:  Rachel L Soon; Neang S Ly; Gauri Rao; Lance Wollenberg; Kuo Yang; Brian Tsuji; Alan Forrest
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

3.  MIC score, a new tool to compare bacterial susceptibility to antibiotics application to the comparison of susceptibility to different penems of clinical strains of Pseudomonas aeruginosa.

Authors:  Cédric Bretonnière; Adeline Maitte; Jocelyne Caillon; Gilles Potel; David Boutoille; Cédric Jacqueline; Christophe Guitton
Journal:  J Antibiot (Tokyo)       Date:  2016-03-30       Impact factor: 2.649

4.  Use of doripenem and risk of seizure and renal impairment in US hospitalized patients: a retrospective cohort study.

Authors:  Scott Chavers; Glenn Magee; Dorothy Baumer; Helen Pai
Journal:  Ther Adv Drug Saf       Date:  2015-12-14

5.  An unusual class of anthracyclines potentiate Gram-positive antibiotics in intrinsically resistant Gram-negative bacteria.

Authors:  Georgina Cox; Kalinka Koteva; Gerard D Wright
Journal:  J Antimicrob Chemother       Date:  2014-03-13       Impact factor: 5.790

Review 6.  Current epidemiology and growing resistance of gram-negative pathogens.

Authors:  David M Livermore
Journal:  Korean J Intern Med       Date:  2012-05-31       Impact factor: 2.884

7.  In vitro Antibacterial Activity of Doripenem against Gram-Negative Blood Isolates in a Korean Tertiary Care Center.

Authors:  Seong-Ho Choi; Mi Young Ahn; Jin-Won Chung; Mi-Kyung Lee
Journal:  Infect Chemother       Date:  2015-09-30

8.  Clinical Experience of Patients Receiving Doripenem-Containing Regimens for the Treatment of Healthcare-Associated Infections.

Authors:  Chien-Ming Chao; Chi-Chung Chen; Hui-Ling Huang; Yin-Ching Chuang; Chih-Cheng Lai; Hung-Jen Tang
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.